Telesis Bio Secures Licensing Deal with Regeneron for On-Site DNA Synthesis Platform
I'm PortAI, I can summarize articles.
Telesis Bio Inc. has secured a licensing deal with Regeneron Pharmaceuticals to implement the Gibson SOLA™ platform at Regeneron's R&D facilities. This platform enhances on-site DNA and gene synthesis, reducing timelines for therapeutic research and drug development. It allows for overnight synthesis of high-fidelity DNA and mRNA, improving iteration speed and data security by eliminating external service providers. This agreement reflects a trend in the industry towards internalizing synthetic biology capabilities to expedite drug discovery.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments